Maintenance Olaparib Provides Long-Term PFS Benefit in Ovarian Cancer
The progression-free survival (PFS) benefit observed with olaparib maintenance persists after treatment completion in patients with advanced ovarian cancer, according to research published in The Lancet Oncology. Five-year follow-up data from the phase 3 SOLO1 trial showed a sustained PFS benefit with 2 years of olaparib maintenance, compared with placebo, in patients with ovarian cancer. “To […]